Improving outcomes in advanced malignant melanoma: update on systemic therapy

Area of Science:

• Oncology
• Dermatology

Background:

• Malignant melanoma incidence is rising globally.
• Surgery is the primary curative treatment, but adjuvant systemic therapy is debated.
• Metastatic melanoma is largely incurable with current standard treatments.

Purpose of the Study:

• To review recent pivotal studies in advanced malignant melanoma systemic therapy.
• To discuss promising new therapeutic agents and approaches.
• To highlight current treatment mainstays and future directions.

Main Methods:

• Review of recent pivotal studies and ongoing clinical trials.
• Discussion of novel systemic agents including targeted therapies and immunotherapies.
• Analysis of combination therapies and single-agent chemotherapy efficacy.

Main Results:

• Single-agent chemotherapy is the mainstay for most advanced melanoma patients.
• Oblimersen combined with dacarbazine improved progression-free survival and response rates.
• Sorafenib and thalidomide show encouraging results in combination therapies.
• Anti-angiogenic drugs and tumor vaccines are under investigation with mixed results.

Conclusions:

• While chemotherapy remains central, novel agents offer new therapeutic avenues for advanced melanoma.
• Combination therapies and targeted agents like BRAF inhibitors are areas of active research.
• Further clinical trials are essential to establish the role of new agents in melanoma treatment.